EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study

Riccardo Candido, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Raffaele Napoli, RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group

Nutrition, Metabolism and Cardiovascular Diseases · 2024

DOI: 10.1016/j.numecd.2024.03.023 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2024. Verfasst von Riccardo Candido und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata, Trieste, Italy. Hauptthemen laut MEDLINE: Comparative Effectiveness Research, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Glycemic Control. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi Italia, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Add-on of basal insulin (BI) to intensify the ongoing therapy with glucagon-like peptide 1 receptor agonist (GLP-1 RA) is recommended, but it is unclear if free or fixed combination of BI and GLP-1 RA produce similar outcomes. A retrospective comparative effectiveness analysis of the add-on of glargine 300 U/mL (Gla-300) to ongoing GLP-1 RA vs. switch to fixed ratio combination of degludec and liraglutide (iDegLira) was performed. METHODS AND RESULTS: Real-world data collected in electronic medical records by 32 Italian diabetes clinics. Propensity score (PS) adjustment was applied to assess changes in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), body weight, and BI dose after 6 months from Gla-300 or iDegLira initiation. Compared to iDegLira group (N = 260), Gla-300+GLP-1 RA group (N = 255) had older age and higher levels of HbA1c (9.1 vs. 8.9%). After 6 months, statistically significant greater FBG improvement [estimated mean difference and 95% confidence intervals: -24.05 mg/dl (-37.04; -11.06; p = 0.0003) and BI dose increase [+0.03 U/kg (95%CI 0.00; 0.06); p = 0.009] were found in the free vs. fixed combination group, although low doses of BI (0.2 U/kg) were reached in both groups. Trends of larger HbA1c and body weight reductions with the free combination were also found, without reaching the statistical significance. CONCLUSION: Although inertia in insulin initiation and titration was documented in both groups, higher benefit on FBG control was obtained with free vs. fixed combination, likely due to a better titration of BI and GLP-1 RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Comparative Effectiveness ResearchDiabetes Mellitus, Type 2Glycated HemoglobinGlycemic ControlHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsAgedFemaleHumansMaleMiddle AgedBiomarkersBlood GlucoseDrug CombinationsDrug SubstitutionElectronic Health RecordsIncretinsInsulin GlargineInsulin, Long-ActingItalyLiraglutideRetrospective StudiesTime FactorsTreatment OutcomeGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

Basal insulinDegludec 100EffectivenessFixed-ratio combinationGLP-1 receptor agonistsGlargine 300NaïveSafetyType 2 diabetesiDegLiraiGlarLixi

Substanzen

BiomarkersBlood GlucoseDrug CombinationsGlycated HemoglobinHypoglycemic AgentsIncretinsInsulin GlargineInsulin, Long-ActingLiraglutideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata, Trieste, Italy.
  • CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. Electronic address: nicolucci@coresearch.it.
  • Medical Affairs, Sanofi S.r.l., Milan, Italy.
  • CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
  • Department of Translational Medical Sciences, Unit of Internal Medicine and Diabetes, Federico II University School of Medicine and Institute of Experimental Endocrinology and Oncology, National Research Council, Napoli…

Förderung

  • Sanofi Italia
  • Sanofi

Zitieren

APA

Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., & RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group (2024). Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2024.03.023

Vancouver

Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R, RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study. Nutrition, Metabolism and Cardiovascular Diseases. 2024. doi:10.1016/j.numecd.2024.03.023

BibTeX
@article{Candido2024,
  author = {Candido, Riccardo and Nicolucci, Antonio and Larosa, Monica and Rossi, Maria Chiara and Napoli, Raffaele and RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group, RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group},
  title = {Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2024},
  doi = {10.1016/j.numecd.2024.03.023}
}
Kostenlos starten →